Efinaconazole - Kaken Pharmaceutical
Alternative Names: Clenafin; IDP-108; Jublia; KP-103Latest Information Update: 25 Jul 2024
At a glance
- Originator Kaken Pharmaceutical
- Developer AIM China; Almirall S.A.; Bausch Health Companies; Dong-A ST; Kaken Pharmaceutical; Main Life Corporation; Tai Tien Pharmaceuticals
- Class Antifungals; Fluorobenzenes; Piperidines; Small molecules; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Onychomycosis
Most Recent Events
- 22 Jul 2024 Alimirall anticipates completion of regulatory review for efinaconazole in China (Topical) in the second half of 2024
- 09 Nov 2023 Almirall expects regulatory submission outcome in Germany and Italy in the second half of 2024
- 10 Nov 2022 Almirall announces intention to launch efinaconazole for Onychomycosis in 2023